Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dapagliflozin + metformin on body weight in type 2 diabetes inadequately controlled on metformin alone
2008-004913-93Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing dapagliflozin + metformin with placebo + metformin (2 arms). Primary endpoint: Change in total body weight at 24 weeks. Started Dec 2008; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-004913-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004913-93.